Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1999-09-13
2002-04-30
Devi, S. (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023500, C530S380000, C530S350000
Reexamination Certificate
active
06380371
ABSTRACT:
INTRODUCTION
1. Field of the Invention
The field of the invention is cell adhesion, particularly selectin mediated cell adhesion, as well as the treatment of disease conditions related thereto.
2. Background of the Invention
Selectin mediated binding plays an important and prominent role in a variety of biological processes. Selectins are lectin like cell adhesion molecules that mediate leukocyte-endothelial, leukocyte-leukocyte, leukocyte-platelet, platelet-endothelial and platelet-platelet interactions. One critical biological process in which selectin mediated binding plays a role is the maintenance of immune surveillance.
Maintenance of immune surveillance depends on the constant recirculation of lymphocytes from the blood through the vascular wall into the tissues and eventually back into the blood. Lymphocyte recruitment from the blood into all secondary lymphoid organs (except the spleen) as well as into many sites of chronic inflammation is mediated by a specialized post-capillary venule called a high endothelial venule. These vessels are defined by the distinct, cuboidal morphology of their endothelial cells and their luminal presentation of ligands for the leukocyte adhesion molecule, L-selectin. This lectin-like adhesion molecule is expressed on all classes of leukocytes in the blood and is responsible for the initial tethering and rolling of a leukocyte on the endothelium prior to subsequent integrin mediated firm arrest and transmigration.
Several selectin ligands have, to date, been identified. The L-selectin endothelial ligands in mouse that have been identified are: CD34, GlyCAM-1, MAdCAM-1 and sgp200. In addition, PSGL-1 has been identified as a leukocyte ligand for P-, E-, and L-selectin. Endothelial ligands for L-selectin in humans are still poorly defined. However, human CD34 and Podocalyxin-like protein (PCLP) have been shown through a variety of assays to have selectin ligand activity.
Although selectin mediated binding events play a critical role in normal physiological processes, disease conditions do exist for which it is desired to regulate or modulate, e.g. limit or prevent, the amount of selectin mediated binding that occurs. Such conditions include: acute or chronic inflammation; autoimmune and related disorders, tissue rejection during transplantation, atherosclerosis, restenosis following angioplasty, damaging thrombotic events, and the like.
As the above conditions all result from selectin mediated binding events, there is great interest in the identification of selectin ligands and the elucidation of the mechanisms underlying such binding events. There is also great interest in the identification of treatment methodologies for these and related disease conditions, as well the identification of active agents for use therein.
As such, there is continued interest in the identification of new selectin ligands and the elucidation of their role(s) in selectin mediated binding events, as well as the development of therapies for disease conditions arising from such binding events.
Relevant Literature
U.S. Pat. No. 5,705,623 describes a podocalyxin like protein expressed on glomular epithelial cells. Sassetti et al.,
J. Exp. Med.
(Jun. 15, 1998) 187:1965-1975 discloses the role of human PCLP as a selectin ligand. Other references describing podocalyxin and homologues thereof include: Kershaw et al.,
J. Biol.
Chem. (Jun. 20, 1997) 272: 15708-15714; Kershaw et al.,
J. Biol.
Chem. (Dec. 8, 1995) 270: 29439-29446; McNagny et al.,
J. Cell Biol.
(Sep. 22, 1997) 138: 1395-1407; and Kerjaschki et al.,
J. Cell Biol.
(1984) 98:1591-1596. Hub & Rot, Am. J. of Pathology (March 1998) 152:749-757 and Middleton et al.,
Cell.
(Oct. 31, 1997) 91:385-395 provide discussions of the role of chemokines in leukocyte trafficking.
References providing background information on L-selectin binding include: Lasky et al.,
Cell
(Jun. 12, 1992) 69:927-938; Baumhueter et al.,
Science
(Oct. 15, 1993) 262: 436-438; Girard & Springer,
Immunology Today
(1995) 16: 449; Rosen & Bertozzi,
Current Opinion in Cell Biology
(1994) 6: 663-673; Celi et al.,
Seminars in Hematology
(1997) 34: 327-335; as well as U.S. Pat. No. 5,580,862.
SUMMARY OF THE INVENTION
Nucleic acid compositions encoding novel polypeptide products with selectin ligand and/or chemokine presenting activity, as well as the polypeptide products (endoglycans) encoded thereby and methods for producing the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including diagnostic applications, and therapeutic agent screening applications, as well as in therapeutic applications. Also provided are methods of treating disease conditions associated with selectin mediated binding events, such as acute and chronic inflammation, autoimmune diseases and related disorders, tissue rejection and the like.
REFERENCES:
patent: 5705623 (1998-01-01), Wiggins et al.
patent: 5723315 (1998-03-01), Jacobs et al.
patent: 365894 (1990-05-01), None
Kershaw et al. J. Biol. Chem. 270: 29439-29446, 1995.*
Patrassi et al. Folia Haematol., Leipzig 117: 369-376, 1990.*
Lehninger AL. Principles of Biochemistry, Worth Publishers, Inc., New York, Chapter 27, pp. 793-836, 1982.*
Adams et al. Nature Genetics 4: 256-267, 1993, abstract.*
Kerjaschki, et al. (1984), “Identification and Characterization of Podocalyxin-the major Sialoprotein of the Renal Glomerular Epithelial Cell,”Journal of Cell Biologyvol. 98:1591-1596.
Kershaw, et al. (1997), “Molecular Cloning and Characterization of Human Podocalyxin-like Protein,”Journal of Biological Chemistryvol. 272(25):15708-15714.
Middleton, et al. (1997), “Transcytosis and Surface Presentation of IL-8 by Venular Endothelial Cells,”Cellvol. 91:385-395.
McNagny, et al. (1997), “Thrombomucin, a Novel Cell Surface Protein that Defines Thrombocytes and Multipotent Hematopoietic Progenitors,”Journal of Cell Biologyvol. 138(6):1395-1407.
Sassetti, et al. (1998), “Identification of Podocalyxin-like Protein as a High Endothelial Venule Ligand for L-Selectin: Parallels to CD34,”J. Exp. Med. vol. 187(12):1965-1975.
Rosen Steven D.
Sassetti Christopher M.
Borden Paula A.
Bozicevic Field & Francis LLP
Devi S.
Field Bret
The Regents of the University of California
LandOfFree
Endoglycan: a novel protein having selectin ligand and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Endoglycan: a novel protein having selectin ligand and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endoglycan: a novel protein having selectin ligand and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2873038